Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements (mechanism of action, general muscle toxicity risk, and LDL/HDL directionality) are broadly supported by the provided label excerpts, but multiple numeric/characterization claims and study-specific assertions are not supported by the provided labeling text. Several safety statements about persistence/permanence and stopping advice are unsupported.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that inhibits cholesterol production in the liver.
DESCRIPTION and 12.1/12.2: Atorvastatin is an inhibitor of HMG-CoA reductase; liver is the primary site of action and cholesterol synthesis. (Provided excerpts support mechanism and hepatic site.)
Lipitor lowers LDL (bad) cholesterol levels.
12.1 Mechanism of Action and 12.2/12.1: LIPITOR reduces total-C and LDL-C (and in animal/clinical descriptions).
Lipitor increases HDL (good) cholesterol levels.
12.1 Mechanism of Action: 'variable increases in HDL-C and apolipoprotein A-1' and 'increases HDL-C' in some populations.
Lipitor is used to treat cholesterol-related conditions.
1 INDICATIONS AND USAGE and 2.1: Lipid-altering therapy as adjunct for hypercholesterolemia; clinical section includes hyperlipidemia/mixed dyslipidemia.
Lipitor can cause muscle pain, stiffness, or cramping, which can affect flexibility.
5.1 Skeletal Muscle: statins can cause myopathy defined as muscle aches or muscle weakness; patients should report muscle pain, tenderness, or weakness. (Label excerpt does not mention flexibility directly.)
Muscle pain and weakness are reported by up to 10% of patients taking Lipitor.
6.1 provides muscle-related adverse reactions (e.g., myalgia, muscle spasms, musculoskeletal pain, pain in extremity), each listed with incidence percentages in a table. (However, 'up to 10%' is not directly evidenced in provided excerpts as a single combined figure.)
Unsupported Statements
Muscle pain and weakness are reported by up to 10% of patients taking Lipitor.
The provided label excerpt lists specific muscle-related adverse reactions with incidence values (e.g., myalgia 3.5%, muscle spasms 3.6%, musculoskeletal pain 3.8%—all 'any dose' table values shown), but does not support a combined 'up to 10%' statement.
A study in the Journal of Clinical Pharmacology reported significant reductions in muscle strength and flexibility in patients taking Lipitor compared with placebo after 12 weeks.
No Journal of Clinical Pharmacology study or 12-week muscle strength/flexibility outcomes are mentioned in the provided label excerpts.
In that study, 60 patients with high cholesterol were randomly assigned to receive Lipitor or placebo.
No such study design/sample size appears in the provided label excerpts.
A study in the Journal of Cardiovascular Pharmacology reported that CoQ10 supplements resulted in significant reductions in muscle pain and weakness compared with placebo in patients taking CoQ10.
No CoQ10 study or Journal of Cardiovascular Pharmacology trial is included in the provided label excerpts.
The article states that most patients taking Lipitor do not experience significant reductions in flexibility.
No excerpted label content supports flexibility-specific outcomes or such a conclusion.
The article states Lipitor is not known to cause permanent damage to muscles.
The provided label excerpts describe rhabdomyolysis/myopathy and management but do not state that permanent muscle damage is 'not known' or include permanence language.
The article states CoQ10 supplements are generally safe to take with Lipitor.
The provided label excerpts do not discuss CoQ10 supplementation or safety with atorvastatin.
The article states consulting a doctor before stopping Lipitor is advised because stopping may increase the risk of heart disease and stroke.
The provided label excerpts do not include any statement about stopping atorvastatin increasing heart disease/stroke risk or advice about consulting a doctor before stopping due to those risks.
Coenzyme Q10 (CoQ10) is described as an antioxidant involved in energy production within cells.
No CoQ10 definition is present in the provided label excerpts.
Contradictions
Low
AI Statement
The article states Lipitor is not known to cause permanent damage to muscles.
Label Reference
5.1 Skeletal Muscle includes rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria and discusses discontinuation in suspected myopathy; the excerpt does not support the 'not known to cause permanent damage' claim and therefore this is treated as unsupported rather than a direct contradiction.
Important Omissions
Boxed warnings / contraindications / specific major drug-interaction warnings are not addressed in the AI response.
Importance:
Moderate
Label-supported monitoring/management language for suspected myopathy (e.g., discontinue if markedly elevated CPK occurs or myopathy diagnosed/suspected; consider closer monitoring and temporary withholding/discontinuation in acute serious conditions) is not included in the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported reassurance/permanence language and unsupported supplementation claims (CoQ10 safety) could mislead interpretation of risk; numeric precision ('up to 10%') and study-specific efficacy claims are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Multiple statements reference specific journal studies, CoQ10, and permanence/stopping-risk assertions that are not present in the provided FDA label excerpts.
Suggested Improvement
Restrict claims to label-supported content from the provided sections (e.g., mechanism via HMG-CoA reductase inhibition, LDL/HDL effects directionality, and myopathy/rhabdomyolysis warnings) and remove or qualify study-specific CoQ10 and numeric 'up to 10%' assertions unless directly supported by the label text provided.